Federal Appeals Court Restricts Mifepristone Access, Impacting Abortion Availability Nationwide
A federal appeals court has issued a ruling that restricts the distribution of mifepristone, a common abortion pill, by mandating that it be obtained in person at clinics rather than through mail. This decision by the New Orleans-based 5th U.S. Circuit Court of Appeals represents a significant challenge to abortion access across the United States, particularly affecting states with stringent abortion bans. The ruling is expected to be appealed to the U.S. Supreme Court, which had previously preserved access to mifepristone in a 2024 decision. The court's decision has been met with criticism for its potential to disproportionately impact rural communities, low-income individuals, people with disabilities, survivors of intimate partner violence, and communities of color. 
